NEWS & UPDATES
Recruitment:
We are 76% of the way to achieving our target (5000 patients)!
Check out Mount Sinai's article on the ICARUS-IBD study:
https://reports.mountsinai.org/article/gi2021-02-icarus
Our Publications:
1. McGregor CG, Adams A, Sadler R, et al.
Maintenance therapy with infliximab or vedolizumab in IBD is not associated with increased SARS-CoV-2 seroprevalence: UK experience in the 2020 pandemic
Gut Published Online First: 12 February 2021. doi: 10.1136/gutjnl-2021-324116.
2. Wong SY, Gold S, Accorsi EK, Cowger TL, Wiseman D, Navalurkar R, Dixon R, Helmus DS, CiTIStudy Group, Firpo-Betancourt A, Mendu DR, Zolla-Pazner S, Cadwell K, Colombel JF. Safety of administering biologics to IBD patients at an outpatient infusion center In New York City during the COVID-19 pandemic: Sars-CoV-2 seroprevalence and clinical and social characteristics. medRxiv 2021.03.15.21253615; doi: https://doi.org/10.1101/2021.03.15.21253615.
3. Wellens J., Colombel J-F., Satsangi JJ., Wong S-Y.
SARS-CoV-2 vaccination in IBD: past lessons, current evidence and future challenges.
J Crohn’s Colitis 2021:1–36. Doi: 10.1093/ecco-jcc/jjab046.
4. Wong SY, Dixon R, Martinez Pazos V, Gnjatic S, Colombel JF, Cadwell K; ICARUS-IBD Working Group. Serologic Response to Messenger RNA Coronavirus Disease 2019 Vaccines in Inflammatory Bowel Disease Patients Receiving Biologic Therapies.
Gastroenterology. 2021 Apr 20: S0016-5085(21)00648-X. doi: 10.1053/j.gastro.2021.04.025.
5. Anna L McNaughton, Robert S Paton, Matthew Edmans, Jonathan Youngs, Judith Wellens, Craig P Thompson
Fatal COVID-19 outcomes are associated with an antibody response targeting epitopes shared with endemic coronaviruses.medRxiv 2021.05.04.21256571; doi: https://doi.org/10.1101/2021.05.04.21256571
6. Selim R, Wellens J, Marlow L, Satsangi JJ.
SARS-CoV-2vaccination uptake by patients with inflammatory bowel disease on biological therapy.
The Lancet, Gastroenterology & Hepatology. 2021 Oct 13. DOI: https://doi.org/10.1016/S2468-1253(21)00347-2
Newsletters:
